全文获取类型
收费全文 | 4845篇 |
免费 | 462篇 |
国内免费 | 195篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 46篇 |
妇产科学 | 18篇 |
基础医学 | 266篇 |
口腔科学 | 47篇 |
临床医学 | 950篇 |
内科学 | 628篇 |
皮肤病学 | 12篇 |
神经病学 | 474篇 |
特种医学 | 66篇 |
外科学 | 182篇 |
综合类 | 462篇 |
一般理论 | 1篇 |
预防医学 | 771篇 |
眼科学 | 28篇 |
药学 | 890篇 |
6篇 | |
中国医学 | 554篇 |
肿瘤学 | 85篇 |
出版年
2024年 | 5篇 |
2023年 | 96篇 |
2022年 | 137篇 |
2021年 | 235篇 |
2020年 | 221篇 |
2019年 | 283篇 |
2018年 | 221篇 |
2017年 | 227篇 |
2016年 | 204篇 |
2015年 | 176篇 |
2014年 | 348篇 |
2013年 | 572篇 |
2012年 | 291篇 |
2011年 | 295篇 |
2010年 | 201篇 |
2009年 | 206篇 |
2008年 | 214篇 |
2007年 | 219篇 |
2006年 | 203篇 |
2005年 | 144篇 |
2004年 | 125篇 |
2003年 | 112篇 |
2002年 | 93篇 |
2001年 | 90篇 |
2000年 | 63篇 |
1999年 | 42篇 |
1998年 | 63篇 |
1997年 | 57篇 |
1996年 | 36篇 |
1995年 | 34篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 27篇 |
1991年 | 20篇 |
1990年 | 12篇 |
1989年 | 15篇 |
1988年 | 17篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 20篇 |
1984年 | 19篇 |
1983年 | 11篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 12篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 6篇 |
1974年 | 3篇 |
排序方式: 共有5502条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《Sleep medicine》2021
BackgroundTheoretical models argue that coping reduces stress responses, yet no studies have tested whether coping moderates the prospective stress effects on sleep in daily life.PurposeThis study tested if coping moderates the stress-sleep association using a daily, intensive longitudinal design across 7–12 days.Methods326 young adults (Mage = 23.24 ± 5.46) reported perceived stress and coping (problem-focused, emotional-approach, and avoidance) every evening between 20:00–02:00, providing over 2400 nights of sleep data and 3000 stress surveys from all participants. Actigraphy and sleep diaries measured total-sleep-time and sleep efficiency. Multilevel models tested the interaction effects of within- and between-person stress and coping on sleep.ResultsWithin-person problem-focused and emotional-approach coping moderated the within-person stress effects on actigraphic total-sleep-time (both p = 0.02); higher stress predicted shorter total-sleep-time only during high use of problem-focused or emotional-approach coping (both p = 0.01). Between-person avoidance moderated the between-person stress effect on actigraphic total-sleep-time (p = 0.04); higher stress predicted shorter total-sleep-time for high avoidance coping (p = 0.02). Within-person emotional-approach coping buffered the between-person stress effect on actigraphic sleep efficiency (p = 0.02); higher stress predicted higher sleep efficiency for high emotional-approach coping (p = 0.04).ConclusionsThis study showed that daily coping moderates the effects of evening stress on sleep that night. More efforts to cope with stress before bedtime had a short-term cost of shorter sleep that night. However, high use of emotional-approach coping buffered the impact of stress to promote sleep efficiency. 相似文献
5.
6.
目的:建立大黄特征化学成分和抗氧化活性相关联的二维指纹图谱,研究大黄抗氧化活性物质。方法:利用高效液相多检测器联用的抗氧化活性成分在线检测体系,对大黄中化学成分进行检测,共鉴定出大黄中化学成分15种;其中8种具有抗氧化活性;然后采用清除效率为指标对各活性成分的抗氧化活性进行评价。结果:结果发现化合物葡萄糖紫丁香酸、腺嘌呤、没食子酸、儿茶素或表儿茶素、双花母草素、2-O-桂皮酰-没食子酰葡萄糖等具有较强的清除ABTS·+的活性,而蒽醌类成分对ABTS·+的清除作用较弱。结论:采用HPLC-ABTS-DAD-Q-TOF/MS对大黄中的抗氧化活性成分进行快速分析鉴定,初步阐明大黄在抗氧化环节起作用的效应物质。 相似文献
7.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献8.
9.
10.
A. Trovato S. Kirjavainen E. M. Galati A. M. Forestieri L. Iauk 《Phytotherapy research : PTR》1995,9(8):591-593
The decoction of Sclerocarya birroea Hochst. shows hypoglycaemic effects, an increase in plasma IRI in normal rats and an incremented oral-glucose tolerance. The decoction is also active against diet-induced hypercholesterolaemia. 相似文献